Edition:
India

bluebird bio Inc (BLUE.OQ)

BLUE.OQ on NASDAQ Stock Exchange Global Select Market

213.35USD
16 Feb 2018
Change (% chg)

$4.70 (+2.25%)
Prev Close
$208.65
Open
$206.05
Day's High
$213.60
Day's Low
$205.50
Volume
196,739
Avg. Vol
270,579
52-wk High
$222.00
52-wk Low
$73.95

Select another date:

Thu, Jan 25 2018

BRIEF-Celgene Says Bluebird Car-T Therapy Remains A Top Priority

* CELGENE CEO SAYS WORKING WITH BLUEBIRD BIO TO DEVELOP BB2121 CAR-T THERAPY FOR MYELOMA REMAINS A TOP PRIORITY

Bluebird to seek approvals for three treatments by end of 2019

U.S. biotech bluebird bio Inc, which does not yet have any marketed products, expects to be able to file for regulatory approval of three novel treatments by the end of 2019, chief executive Nick Leschly announced on Tuesday.

CORRECTED-Bluebird to seek approvals for three treatments by end of 2019

Jan 9 U.S. biotech bluebird bio Inc, which does not yet have any marketed products, expects to be able to file for regulatory approval of three novel treatments by the end of 2019, chief executive Nick Leschly announced on Tuesday.

BRIEF-Bluebird Bio Expects Three Regulatory Filings By End 2019

* BLUEBIRD BIO CEO SAYS EXPECTS THREE REGULATORY FILINGS BY END 2019

BRIEF-Merck And Bluebird Bio Sign Supply Agreement For Commercial Production Of Viral Vectors

* MERCK AND BLUEBIRD BIO SIGN SUPPLY AGREEMENT FOR COMMERCIAL PRODUCTION OF VIRAL VECTORS Source text - http://bit.ly/2DfAvDy Further company coverage: (Gdynia Newsroom)

BRIEF-Bluebird Bio Prices Public Offering Of 3.2 Mln Shares At $185/Share

* BLUEBIRD BIO ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Bluebird Bio Announces Proposed Public Offering Of Common Stock

* BLUEBIRD BIO ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-bluebird bio And TC BioPharm Announce Strategic Collaboration

* BLUEBIRD BIO AND TC BIOPHARM ANNOUNCE STRATEGIC COLLABORATION TO RESEARCH AND DEVELOP GAMMA DELTA CAR T CELL PRODUCT CANDIDATES FOR CANCER IMMUNOTHERAPY

BRIEF-Bluebird Bio Acquires Manufacturing Facility In North Carolina

* BLUEBIRD BIO ACQUIRES MANUFACTURING FACILITY IN NORTH CAROLINA AND EXECUTES MULTIPLE GLOBAL SUPPLY AGREEMENTS TO ENHANCE ABILITY TO DELIVER GENE THERAPIES TO PATIENTS Source text for Eikon: Further company coverage:

BRIEF-Bluebird Bio says to receive $15 mln option exercise payment from Celgene​

* Bluebird Bio Inc - to receive $15 million option exercise payment from Celgene​

Select another date: